Skip to main content
Erschienen in: Infection 3/2016

28.04.2016 | Editorial

Blue sky and some shadows: new antibiotics and new superbugs

The ECCMID 2016 in Amsterdam

verfasst von: Johannes R. Bogner

Erschienen in: Infection | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Excerpt

What is the latest news in infectious diseases and clinical microbiology? This question is so important for about 11,000 physicians, researchers, developers and also for the diagnostic and pharmaceutical industry from almost all countries on this planet that they travel to the place where they can see it all at once: about 3000 scientific contributions in oral presentations, posters and e-posters. For many, the focuses of interest were two topics: the spread of resistant organisms including what can be done against it and the development of new antibacterials. …
Literatur
1.
Zurück zum Zitat Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.CrossRefPubMed Liu YY, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16:161–8.CrossRefPubMed
2.
Zurück zum Zitat Zurfuh K, et al. Occurrence of the plasmid-borne mcr-1 colistin resistance gene in extended-spectrum-beta-lactamase-producing Enterobacteriaceae in river water and imported vegetable samples in Switzerland. Antimicrob Agents Chemother. 2016;60:2594–5.CrossRefPubMed Zurfuh K, et al. Occurrence of the plasmid-borne mcr-1 colistin resistance gene in extended-spectrum-beta-lactamase-producing Enterobacteriaceae in river water and imported vegetable samples in Switzerland. Antimicrob Agents Chemother. 2016;60:2594–5.CrossRefPubMed
3.
Zurück zum Zitat Jung N, Lehmann C, Fatkenheuer G The “choosing wisely”: initiative in infectious diseases. Infection. 2015. Jung N, Lehmann C, Fatkenheuer G The “choosing wisely”: initiative in infectious diseases. Infection. 2015.
4.
Zurück zum Zitat Kern WV. New antibacterial agents on the market and in the pipeline. Internist (Berl). 2015;56:1255–63.CrossRef Kern WV. New antibacterial agents on the market and in the pipeline. Internist (Berl). 2015;56:1255–63.CrossRef
6.
Zurück zum Zitat Heizmann WR, et al. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37–43.CrossRefPubMedPubMedCentral Heizmann WR, et al. Clinical efficacy of tigecycline used as monotherapy or in combination regimens for complicated infections with documented involvement of multiresistant bacteria. Infection. 2015;43:37–43.CrossRefPubMedPubMedCentral
Metadaten
Titel
Blue sky and some shadows: new antibiotics and new superbugs
The ECCMID 2016 in Amsterdam
verfasst von
Johannes R. Bogner
Publikationsdatum
28.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Infection / Ausgabe 3/2016
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-016-0898-7

Weitere Artikel der Ausgabe 3/2016

Infection 3/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.